Importance Colorectal cancer (CRC) is the third most common cause of cancer mortality
worldwide with more than 1.85 million cases and 850 000 deaths annually. Of new …

The patients with high microsatellite instability (MSI-H)/mismatch repair deficient (dMMR)
tumors recently have been reported that can benefit from immunotherapy, and MSI can be …

PURPOSE KEYNOTE-164 (NCT02460198) evaluated the antitumor activity of
pembrolizumab in previously treated, metastatic, microsatellite instability–high/mismatch …

Background Metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high
(MSI-H) colorectal cancer has a poor prognosis after treatment with conventional …

Colorectal cancer (CRC) is one of the most common malignancies in the United States.
Every 3 years, the American Cancer Society provides an update of CRC incidence, survival …

Colorectal cancer (CRC) is the third most common cancer and the fourth most common
cause of cancer-related death. Most cases of CRC are detected in Western countries, with its …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

Background Somatic mutations have the potential to encode “non-self” immunogenic
antigens. We hypothesized that tumors with a large number of somatic mutations due to …

The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

Initial results by Le and colleagues, which were published in the June 25, 2015 issue of the
New England Journal of Medicine, report significant responses of cancers with microsatellite …